<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id>
      <journal-id journal-id-type="publisher-id">EID</journal-id>
      <journal-title-group>
        <journal-title>Emerging Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1080-6040</issn>
      <issn pub-type="epub">1080-6059</issn>
      <publisher>
        <publisher-name>Centers for Disease Control and Prevention</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19891893</article-id>
      <article-id pub-id-type="pmc">2857228</article-id>
      <article-id pub-id-type="publisher-id">09-0384</article-id>
      <article-id pub-id-type="doi">10.3201/eid1511.090384</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>East African Trypanosomiasis in a Pregnant Traveler</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Nadjm</surname>
            <given-names>Behzad</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Van Tulleken</surname>
            <given-names>Chris</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Macdonald</surname>
            <given-names>Douglas</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chiodini</surname>
            <given-names>Peter L.</given-names>
          </name>
        </contrib>
        <aff id="aff1">The Hospital for Tropical Diseases, London, UK (B. Nadjm, C. Van Tulleken, P.L. Chiodini)</aff>
        <aff id="aff2">London School of Hygiene and Tropical Medicine, London (P.L. Chiodini, B. Nadjm)</aff>
        <aff id="aff3">Chelsea and Westminster Hospital, London (D. Macdonald)</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Address for correspondence: Behzad Nadjm, Clinical Research Unit, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK; email: <email xlink:href="behzad.nadjm@lshtm.ac.uk">behzad.nadjm@lshtm.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2009</year>
      </pub-date>
      <volume>15</volume>
      <issue>11</issue>
      <fpage>1866</fpage>
      <lpage>1867</lpage>
      <kwd-group kwd-group-type="author">
        <title>Keywords: </title>
        <kwd>Human African trypanosomiasis</kwd>
        <kwd>Africa</kwd>
        <kwd>pregnancy</kwd>
        <kwd>parasites</kwd>
        <kwd>travelers</kwd>
        <kwd>letter</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p><bold>To the Editor</bold>: Human African trypanosomiasis (HAT) results in a large number of deaths and considerable illness in sub-Saharan Africa. Although the disease is uncommon in returning travelers from that region, awareness of it is important for medical practitioners in areas where the disease is not endemic. The disease can be categorized geographically into West and East African trypanosomiasis caused by <italic>Trypanosoma brucei gambiense</italic> and <italic>T. brucei rhodesiense</italic>, respectively, and clinicopathologically into hemolymphatic (stage I) disease and meningoencephalitic (stage II) disease (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). The East African form of the disease is less common than the West African form and accounts for 10% of the global incidence of trypanosomiasis.</p>
    <p>Relative stability in East African nations may have contributed to the lower incidence of the disease in these countries, but drought and increasing pressure on water sources may lead to an upsurge in East African disease. The increasing ease of global travel and attraction of game safaris and hunting may also lead to increasing exposure in travelers. HAT is treated with toxic drugs in regimens that have changed little for decades. Few published data exist on the treatment of HAT in pregnancy, particularly for East African disease. We describe a case of <italic>T. brucei rhodesiense</italic> infection occurring in a pregnant traveler.</p>
    <p>A 32-year-old woman, 20 weeks pregnant, returned from a 9-day safari trip to Tanzania 8 days before coming to a hospital in London. She described a short history of fever, headache, and soft-tissue swelling of the forehead with severe regional adenopathy. She had evidence of skin necrosis (chancre) (<xref ref-type="fig" rid="F1">Figure</xref>) but no history of tsetse fly bite. Blood tests showed anemia (hemoglobin 9.5 g/dL), leukopenia (1.8 &#xD7; 10<sup>9</sup> cells/L), and thrombocytopenia (60 &#xD7; 10<sup>9</sup> cells/L). A blood film showed trypomastigotes of <italic>T. brucei rhodesiense</italic>. Suramin was initially unavailable for treatment, but because of her deteriorating clinical state, she was treated with 1 dose of pentamidine (4 mg/kg) before suramin was obtained. Suramin was begun 36 hours after admission, initially at 5 mg/kg and increased over the next 2 doses up to 1 g. During the next 48 hours, her fever resolved, and serial blood films showed clearance of the parasites from the blood. A cerebrospinal fluid sample showed no signs of stage II disease, and the patient continued on suramin, completing a standard course as an outpatient. Her pregnancy was closely monitored, and she gave birth at term to a healthy baby girl.</p>
    <fig id="F1" fig-type="figure" position="float">
      <label>Figure</label>
      <caption>
        <p>Chancre at site of tsetse fly bite on forehead of pregnant patient with trypanosomiasis.</p>
      </caption>
      <graphic xlink:href="09-0384-F"/>
    </fig>
    <p>The treatment of choice for stage I HAT caused by <italic>T. brucei gambiense</italic> is parenteral pentamidine (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). No published trials compare pentamidine and suramin in East African trypanosomiasis, but longstanding consensus suggests that suramin is more likely to be efficacious in stage I East African disease (<xref ref-type="bibr" rid="R1"><italic>1</italic></xref>). The basis for this difference in efficacy is unexplained.</p>
    <p>Theoretically, pentamidine may be teratogenic because it inhibits protein and nucleic acid synthesis in vitro (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref>). However, studies in rats found pentamidine to be feticidal but not teratogenic (<xref ref-type="bibr" rid="R3"><italic>3</italic></xref>). Pentamidine has been used extensively for HAT prophylaxis without reported problems (<xref ref-type="bibr" rid="R4"><italic>4</italic></xref>) and has had limited use in pregnant women with <italic>Pneumocystis</italic> <italic>jirovecii</italic> pneumonia. It continues to be recommended in pregnant women with stage I HAT originating in West Africa. Suramin is known to cause a syndrome similar to preeclampsia in pregnant rats (<xref ref-type="bibr" rid="R5"><italic>5</italic></xref>), yet it too has been used in large-scale treatment programs for onchocerciasis, and no fetal or placental effects have been reported in humans (<xref ref-type="bibr" rid="R2"><italic>2</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R6"><italic>6</italic></xref>). We found 1 case report describing successful use of suramin, followed by melarsoprol, in a pregnant woman with HAT (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref>).</p>
    <p>The treatment of stage II disease in pregnancy is problematic, and published information to guide therapy is lacking. Although the effect of arsenicals on fetuses is a concern, case reports have described the successful use of melarsoprol during pregnancy (<xref ref-type="bibr" rid="R7"><italic>7</italic></xref><italic>,</italic><xref ref-type="bibr" rid="R8"><italic>8</italic></xref>); if left untreated, the disease is fatal. Thus, if our patient had stage II disease, use of melarsoprol, which is often given with prednisolone, would have been necessary.</p>
    <p>In pregnant women with West African (<italic>T. brucei gambiense</italic>) stage II disease, either melarsoprol or eflornithine can be used, but neither is effective for East African disease. Although eflornithine can abort early pregnancies and cause disordered organogenesis (<xref ref-type="bibr" rid="R9"><italic>9</italic></xref>), the severe encephalopathy associated with melarsoprol makes eflornithine a preferable option for single-agent treatment. However, nifurtimox&#x2013;eflornithine combination therapy will soon replace single-drug regimens for stage II <italic>T. brucei gambiense</italic> cases (<xref ref-type="bibr" rid="R10"><italic>10</italic></xref>).</p>
    <p>We believed evidence was insufficient to withhold suramin therapy for this highly fatal disease. Because of the uncertainty about effects of pregnancy on the ability to clear trypanosomes, the patient will be followed up for signs of relapse. The danger of HAT should be specifically highlighted for all travelers to trypanasomiasis-endemic regions, particularly pregnant travelers because of potential harm to unborn children.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="citation">
        <p><italic>Suggested citation for this article</italic>: Nadjm B, Van Tulleken C, Macdonald D, Chiodini PL. East African trypanosomiasis in a pregnant traveler [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Nov [<italic>date cited</italic>]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/EID/content/15/11/1866.htm">http://www.cdc.gov/EID/content/15/11/1866.htm</ext-link></p>
      </fn>
    </fn-group>
    <ack>
      <p>P.L.C. is supported by the University College London Hospitals Comprehensive Biomedical Research Centre Infection Theme.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Stich</surname> <given-names>A</given-names></string-name>, <string-name><surname>Abel</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Krishna</surname> <given-names>S</given-names></string-name> <article-title>Human African trypanosomiasis.</article-title><source>BMJ</source> <year>2002</year>;<volume>325</volume>:<fpage>203</fpage>&#x2013;<lpage>6</lpage> <pub-id pub-id-type="doi">10.1136/bmj.325.7357.203</pub-id><pub-id pub-id-type="pmid">12142311</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2. </label>
        <mixed-citation publication-type="book"><string-name><surname>Dollery</surname> <given-names>CT</given-names></string-name> Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; <year>1999</year></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Harstad</surname> <given-names>TW</given-names></string-name>, <string-name><surname>Little</surname> <given-names>BB</given-names></string-name>, <string-name><surname>Bawdon</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Knoll</surname> <given-names>K</given-names></string-name>, <string-name><surname>Roe</surname> <given-names>D</given-names></string-name>, <string-name><surname>Gilstrap</surname> <given-names>LC</given-names> <suffix>III</suffix></string-name> <article-title>Embryofetal effects of pentamidine isethionate administered to pregnant Sprague-Dawley rats.</article-title><source>Am J Obstet Gynecol</source> <year>1990</year>;<volume>163</volume>:<fpage>912</fpage>&#x2013;<lpage>6</lpage><pub-id pub-id-type="pmid">2403167</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Schneider</surname> <given-names>J</given-names></string-name> <article-title>Treatment of human African trypanosomiasis.</article-title><source>Bull World Health Organ</source> <year>1963</year>;<volume>28</volume>:<fpage>763</fpage>&#x2013;<lpage>86</lpage><pub-id pub-id-type="pmid">13992149</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Nash</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wentzel</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lindeberg</surname> <given-names>S</given-names></string-name>, <string-name><surname>Naessen</surname> <given-names>T</given-names></string-name>, <string-name><surname>Jansson</surname> <given-names>L</given-names></string-name>, <string-name><surname>Olovsson</surname> <given-names>M</given-names></string-name>, <etal/><article-title>Placental dysfunction in Suramin-treated rats&#x2013;a new model for pre-eclampsia.</article-title><source>Placenta</source> <year>2005</year>;<volume>26</volume>:<fpage>410</fpage>&#x2013;<lpage>8</lpage> <pub-id pub-id-type="doi">10.1016/j.placenta.2004.07.009</pub-id><pub-id pub-id-type="pmid">15850646</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Anderson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Fuglsang</surname> <given-names>H</given-names></string-name> <article-title>de C Marshall TF. Effects of suramin on ocular onchocerciasis.</article-title><source>Tropenmed Parasitol</source> <year>1976</year>;<volume>27</volume>:<fpage>279</fpage>&#x2013;<lpage>96</lpage><pub-id pub-id-type="pmid">982547</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Lowenthal</surname> <given-names>MN</given-names></string-name> <article-title>Trypanosomiasis successfully treated with suramin in a pregnant woman.</article-title><source>Med J Zambia</source> <year>1971</year>;<volume>5</volume>:<fpage>175</fpage>&#x2013;<lpage>8</lpage></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Buyst</surname> <given-names>H</given-names></string-name> <article-title>Pregnancy complications in Rhodesian sleeping sickness.</article-title><source>East Afr Med J</source> <year>1973</year>;<volume>50</volume>:<fpage>19</fpage>&#x2013;<lpage>21</lpage><pub-id pub-id-type="pmid">4720443</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Pepin</surname> <given-names>J</given-names></string-name>, <string-name><surname>Milord</surname> <given-names>F</given-names></string-name> <article-title>The treatment of human African trypanosomiasis.</article-title><source>Adv Parasitol</source> <year>1994</year>;<volume>33</volume>:<fpage>1</fpage>&#x2013;<lpage>47</lpage> <pub-id pub-id-type="doi">10.1016/S0065-308X(08)60410-8</pub-id><pub-id pub-id-type="pmid">8122565</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10. </label>
        <mixed-citation publication-type="journal"><string-name><surname>Priotto</surname> <given-names>G</given-names></string-name>, <string-name><surname>Kasparian</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ngouama</surname> <given-names>D</given-names></string-name>, <string-name><surname>Ghorashian</surname> <given-names>S</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>U</given-names></string-name>, <string-name><surname>Ghabri</surname> <given-names>S</given-names></string-name>, <etal/><article-title>Nifurtimox-eflornithine combination therapy for second-stage <italic>Trypanosoma brucei gambiense</italic> sleeping sickness: a randomized clinical trial in Congo.</article-title><source>Clin Infect Dis</source> <year>2007</year>;<volume>45</volume>:<fpage>1435</fpage>&#x2013;<lpage>42</lpage> <pub-id pub-id-type="doi">10.1086/522982</pub-id><pub-id pub-id-type="pmid">17990225</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
